Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status:
Suspended
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits
of zanubrutinib in combination with the R-CHOP in treating patients with newly diagnosed
diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called
Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the
combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and
prednisone. It is the most widely used chemoimmunotherapy regimen for DLBCL and is considered
the standard-of-care treatment for patients with DLBCL. Three of the drugs in R-CHOP
(cyclophosphamide, doxorubicin and vincristine) are chemotherapy drugs. Rituximab is a type
of immunotherapy and prednisone is a type of steroids.